{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:47:23Z","timestamp":1789624043021,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":4329,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>Thirty patients with cancer pain completed a double\u2010blind crossover study comparing controlled\u2010release (CR) and immediate\u2010release (IR) oxycodone. In open\u2010label titration (2 to 21 days), these patients were stabilized on IR oxycodone qid. They were then randomized to double\u2010blind treatment with CR oxycodone q12h or IR oxycodone qid for 3 to 7 days followed by crossover at the same daily dose. Mean (\u00b1 SD) pain intensity (0 = none to 10= severe) decreased from a baseline of 6.0 \u00b1 2.2 to 2.7 \u00b1 1.1 after titration with IR oxycodone dosed qid. Pain intensity remained stable throughout double\u2010blind treatment: 2.7 \u00b1 1.9 with CR oxycodone and 2.8 \u00b1 1.9 with IR oxycodone. Acceptability of therapy and pain scores correlated with plasma oxycodone concentrations for each interval and were similar for both medications (IR and CR oxycodone). Adverse events were similar for both formulations. Following repeat dosing under double\u2010blind conditions, oral CR oxycodone administered q12h provided analgesia comparable to IR oxycodone given qid.<\/jats:p>","DOI":"10.1177\/00912700122010375","type":"journal-article","created":{"date-parts":[[2003,7,19]],"date-time":"2003-07-19T09:38:13Z","timestamp":1058607493000},"page":"500-506","source":"Crossref","is-referenced-by-count":54,"title":["Double\u2010Blind, Randomized Comparison of the Analgesic and Pharmacokinetic Profiles of Controlled\u2010 and Immediate\u2010Release Oral Oxycodone in Cancer Pain Patients"],"prefix":"10.1002","volume":"41","author":[{"given":"John E.","family":"Stambaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Reder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Stambaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Stambaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"issue":"1","key":"e_1_2_1_2_2","first-page":"195","article-title":"WHO cancer pain relief programme","volume":"7","author":"Stjernsward J","year":"1988","journal-title":"Cancer Surv"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.1989.11700638"},{"issue":"5","key":"e_1_2_1_5_2","first-page":"510","article-title":"Non\u2010steroidal anti\u2010inflammatory drugs: use and complications","volume":"33","author":"Ng SC","year":"1992","journal-title":"Singapore Med J"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(88)80021-9"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802123380707"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.214"},{"key":"e_1_2_1_9_2","volume-title":"Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain.","author":"American Pain Society","year":"1999"},{"key":"e_1_2_1_10_2","first-page":"381","article-title":"Eukodal ein neues Narkotikum [Eukodal, a new narcotic]","volume":"64","author":"Falk E","year":"1917","journal-title":"Muenchener Med Wochenschr"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.85"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507113130205"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610103351507"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.176"},{"issue":"5","key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.1993.11.5.973","article-title":"Dose\u2010ranging study of oxycodone for chronic pain in advanced cancer","volume":"11","author":"Glare PA","year":"1993","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(93)90101-Z"},{"issue":"1","key":"e_1_2_1_17_2","first-page":"101","article-title":"Analgesic studies of codeine and oxycodone in patients with cancer: II. Comparisons of intramuscular oxycodone and intramuscular morphine and codeine","volume":"207","author":"Beaver WT","year":"1978","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00072-9"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04223.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80182-2"},{"key":"e_1_2_1_21_2","first-page":"151","volume-title":"Advances in Pain Research and Therapy","author":"Stambaugh JE","year":"1991"},{"key":"e_1_2_1_22_2","volume-title":"Principles and Techniques of Human Research and Therapeutics: Selected Topics","author":"Stambaugh JE","year":"1985"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90024-7"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90051-0"},{"issue":"4","key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/026921639300700407","article-title":"A novel morphine sulphate preparation: clinical trial of a controlled\u2010release morphine suspension in cancer pain","volume":"7","author":"Forman WB","year":"1993","journal-title":"Palliat Med"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F00912700122010375","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/00912700122010375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T22:16:34Z","timestamp":1696630594000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/00912700122010375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1177\/00912700122010375"],"URL":"https:\/\/doi.org\/10.1177\/00912700122010375","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}